Abstract Purpose: We investigated the prognostic effect of incorporating metabolic assessment by 18 F-fluoro-2-deoxyglucose uptake on positron emission tomography/computed tomography ( 18 F-FDG-PET/CT) into a conventional staging system in small-cell lung cancer (SCLC). Experimental Design: Seventy-six consecutive patients with pathologically proven SCLC were enrolled. All patients underwent standard treatment after pretreatment Results: Patients with high meanSUV max were significantly related with the established poor prognostic factors, such as higher lactate dehydrogenase (P = 0.04) and extensive disease (ED; P = 0.01). Furthermore, in multivariate analysis, patients with high meanSUV max were associated with poor survival outcomes compared with patients with low meanSUV max [adjusted hazard ratio, 3.74; 95% confidence interval (95% CI), 1.67-8.37; P = 0.001, for death and adjusted hazard ratio, 2.25; 95% CI, 1.21-4.17; P = 0.01for recurrence/progression]. In subgroup analysis, limited disease (LD) with high meanSUV max showed significantly shorter overall survival than LD with low meanSUV max [high versus low meanSUV max , 20.1 months (95% CI, 7.9-23.2) versus 35.3 months (95% CI, 27.6-42.9); P = 0.02]. ED with high meanSUV max had significantly shorter overall survival than ED with low meanSUV max [high versus low meanSUV max , 9.5 months (95% CI, 4.9-13.9) versus 17.7 months (95% CI, 12.0-20.1); P = 0.007]. These findings were replicated in progression-free survival analysis. Conclusions: In SCLC, tumor metabolic activity as assessed by FDG-PET is a significant prognostic factor and identifies subgroups of patients at higher risk of death in both LD and ED SCLC.
limited disease (LD) and extensive disease (ED), based on suitability for radiotherapy. This staging system anatomically defines the extent of the disease and selects a subset of patients in whom a combined treatment modality can improve survival. Moreover, tumor stage is the most important prognostic factor of SCLC over performance status, weight loss, gender, lactate dehydrogenase (LDH), and albumin (4, 5) . However, despite its practical usefulness and prognostic advantage, the two-stage system is inadequate for predicting survival in some patients. This is particularly relevant for data from a few studies that have shown that the addition of radiotherapy to chemotherapy provides a survival benefit in a favorable subset of ED patients (6, 7). Furthermore, data reported by Shepherd et al. (8) has shown that patients with very limited SCLC, including stage I or II classified by the tumor-node-metastasis system, have improved prognoses compared with patients with usual limited SCLC who present with advanced mediastinal adenopathy. These data suggest that the two-tiered staging system based only on anatomic imaging may define prognostically heterogeneous groups. Thus, more discriminative prognostic markers would be needed, allowing better stratification for appropriate therapy and more accurate predictions of treatment outcome and survival.
Positron emission tomography (PET) imaging using 18 Ffluoro-2-deoxyglucose ( 18 F-FDG) is a novel imaging technique based on the increased rate of glucose uptake in malignant cell. An association between tumor glycolytic activity and tumor proliferation prognosis remains controversial. A number of studies have found that the rate of 18 F-FDG uptake is correlated with tumor growth rate (9, 10) or survival in a variety of malignant tumors (11 -14) . However, some studies have reported that 18 F-FDG uptake is not an independent prognostic factor of survival (15 -17) . Although contradictory results have also been reported, 18 F-FDG-PET has continued to be proposed as a noninvasive measurement of the biological aggressiveness of the tumor and prognostic factor of patient outcome. More recently, 18 F-FDG-PET imaging has been increasingly applied to the staging of SCLC due to high sensitivity and specificity for differentiating ED from LD (18 -20) . Regarding the tumor characteristics, FDG uptake by PET may also have a major role in predicting the survival of SCLC.
Therefore, we conducted the present study to determine if a model including a conventional tumor stage and 18 F-FDG uptake in pretreatment PET/computed tomography (CT) imaging is more accurate for predicting survival than the tumor stage alone in patients with SCLC.
Materials and Methods
Patients. From February 2003 to December 2007, we enrolled consecutive patients with newly diagnosed, histologically or cytologically proven, and untreated SCLC. Complete staging procedures included history taking and physical examination, chest radiography, bone scintigraphy (if needed), magnetic resonance imaging of brain, and hematologic and biochemical tests as well as 18 F-FDG-PET/CT scanning within 2 wk before the first treatment. Patients who had any lesions that could not be confirmed by 18 F-FDG-PET/CT image underwent further anatomic imaging or pathologic biopsy. This study was approved by the institutional review board of the Yonsei University College of Medicine (Seoul, Republic of Korea). All patients gave written, informed consent before enrollment.
Treatment and response evaluation. Patients with LD underwent concurrent chemoradiotherapy, which consisted of six cycles of chemotherapy and thoracic radiotherapy. Irradiation on the chest was initiated on day 1 of the second cycle of chemotherapy with 1. (21) . After completion of treatment, patients were evaluated with CT scans every 3 mo for 1 y, every 6 mo in the following year, and yearly thereafter.
PET imaging. All patients fasted for at least 6 h before an 18 F-FDG-PET/CT scan. When plasma glucose level before administration of 18 F-FDG was below 130 mg/dL, scanning was done. Scanning was initiated 60 min after administration of FDG. Low-dose noncontrast CT scans were obtained for nonuniform attenuation correction. Images from the neck to the proximal thighs were obtained using the Phillips Gemini PET/CT scanner (Phillips-ADAC Medical Systems) with a spatial resolution of 5.3 mm in the center of the field of view. Data were acquired in a three-dimensional mode after the i.v. administration of 370 to 444 MBq of 18 F-FDG. After PET imaging, contrastenhanced CT images were acquired (i.v. bolus 60% w/v at 1.5-2.0 mL/s). The obtained PET images were reconstructed using an iterative reconstruction algorithm, specifically the low-action maximal likelihood algorithm.
PET interpretation. Two experienced nuclear medicine specialists who were unaware of the clinical information were responsible for reading the 18 F-FDG-PET/CT images. In the cases of discrepancy, a consensus was reached and was used for analysis. Positive malignant FDG uptake was defined as an abnormal increase in comparison with the background activity in the surrounding tissue. The standardized uptake values (SUV) were generated for malignant lesions, such as primary tumor, lymph nodes, and metastatic lesions except brain metastasis. The SUV was measured by region-of-interest analysis and calculated as the dose detected in the lesion divided by the injected dose, with correction for body weight (ACi/g). The maximal SUV (SUV max ) was the peak SUV in one pixel with the highest counts within the region of interest. For further analyses, we chose the malignant
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Results
Patient characteristics. The patient baseline characteristics are presented in Table 1 . In total, 88 eligible patients were enrolled. Four patients died early due to treatment-related toxicities and eight patients refused to continue the treatment and were lost to follow-up. Thus, 76 patients were analyzed. The median age of the patients was 56 years (range, 50-78 years). Initial chemotherapy regimens included IP (80%) and EP (20%). The median number of cycles of chemotherapy given was 6 (range, 2-6). The median relative dose intensities of irinotecan, etoposide, and platinum were 0.94 [95% confidence interval (95% CI), 0.89-0.96], 0.93 (95% CI, 0.87-1.01), and 0.83 (95% CI, 0.78-0.86), respectively. All LD patients received thoracic radiation, with a median total dose of 54.0 Gy (95% CI, 38.7-58.1). Among the 35 patients with LD who showed complete remission or partial remission after chemoradiotherapy, 31 patients underwent a scheduled prophylactic cranial irradiation and four patients took palliative radiotherapy for overt brain metastases, which developed before the prophylactic cranial irradiation. SUV and responses. A total of 76 patients underwent 18 F-FDG-PET/CT imaging. The median plasma glucose level before 18 F-FDG-PET/CT imaging was 96 mg/dL (range, 81-120 mg/dL). The total number of lesions analyzed was 326; primary tumors were 23%, lymph node 31%, distant metastasis 35%, and unspecified site 11%. The median number of lesions analyzed per patient was 4. The median size of the lesions included in the analysis was 2.2 cm and was not different between LD and ED patients (Mann-Whitney U test, P = 0.26). The meanSUV max of the 76 patients ranged from 2.9 to 36.0, with a median value of 8.7. When patients were divided into two groups according to the median value of meanSUV max , the patients with high meanSUV max were more likely to have higher LDH (P = 0.04) and to be ED (P = 0.01), compared with the patients with low meanSUV max ( Table 1) . For the responses to the first treatment, the high meanSUV max group did not Fig. 1B] . In a univariate analysis of PFS, age, gender, and performance status were not significant predictors but LDH, stage, and meanSUV max . In a multivariate analysis of PFS, LDH, stage, and meanSUV max confirmed to be independent predictors ( Table 2 ). The high meanSUV max group had a higher risk of recurrence/progression, with an adjusted hazard ratio of 2.25 (95% CI, 1.21-4.17, P = 0.01), compared with the low meanSUV max group. Similar associations between meanSUV max and survival outcome were observed when meanSUV max was analyzed as a continuous variable.
Subgroup analysis by stage. A strong association between meanSUV max and survival was also found within each stage. LD with high meanSUV max showed significantly shorter OS than LD with low meanSUV max [median OS for high meanSUV max versus low meanSUV max , 20.1 months (95% CI, 7.9-23.2) versus 35.3 months (95% CI, 27.6-42.9); P = 0.02; Fig. 2A ]. ED with high meanSUV max also had significantly shorter OS than the same stage with low meanSUV max [median OS for high meanSUV max versus low meanSUV max , 9.5 months (95% CI, 4.9-13.9) versus 17.7 months (95% CI, 12-20.1); P = 0.007; Fig. 2A ].
This finding was replicated in a PFS analysis. In patients with LD, median PFS of high meanSUV max was shorter than those of low meanSUV max [median PFS for high meanSUV max versus low meanSUV max , 10.7 months (95% CI, 6.8-14.5) versus 23.5 months (95% CI, 19.4-37.9); P = 0.05; Fig. 2B ]. In patients with ED, high meanSUV max was associated significantly with shorter PFS [median PFS for high meanSUV max versus low meanSUV max , 6.0 months (95% CI, 2.2-9.8) versus 10.5 months (95% CI, 7.6-13.3); P = 0.04; Fig. 2B] .
Among the LD patients, the high meanSUV max group showed a better response than the low meanSUV max group, although the difference was not statistically significant (CR+PR; 100% versus 77%, P = 0.07; Table 3 ). Distant metastases developed more frequently in the LD with high meanSUV max group than in the LD with low meanSUV max group without statistical significance (71.4% versus 52.8%, P = 0.07).
Three prognostically homogenous groups. Dividing the subjects into four groups using the combined criteria of mean-SUV max and stage, the LD patients with high meanSUV max . When the two series with similar survival were treated as a single group, LD with low meanSUV max , LD with high meanSUV max and ED with low meanSUV max , and ED with high meanSUV max were defined as group 1, 2, and 3, respectively. The three groups defined by the combined criteria showed significant differences in OS [median OS for groups 1, 2, and 3 were 31.1 (95% CI, 20.1-42.2), 19.3 (95% CI, 6 .0-32.7), and 8.5 months (95% CI, 5.5-11.5), respectively; P < 0.001; Fig. 3A] . When group 1 was used as the reference group, adjusted hazard ratios for death in groups 2 and 3 were 5.47 (95% CI, 1.64-18.24) and 14.44 (95% CI, 4.52-46.14), respectively (P < 0.001; Table 4 ). These findings were replicated in the PFS analysis ( Fig. 3B; Table 4) .
SUV values. We tested three variables based on the SUV max : meanSUV max (median = 8.7, 95% CI, 8.2-10.5), which was defined as the mean of the SUV max ; primarySUV max (median = 9.3, 95% CI, 8.9-11.2), which was the SUV max measured in the primary lesion; and peakSUV max (median = 9.9, 95%CI, 9.9-12.1), which was the highest of the SUV max values. In Spearman's test with three SUV variables, there were significant correlation between meanSUV max and primarySUV max (q = 0.54, P = 0.04), between meanSUV max and peakSUV max (q = 0.55, P = 0.03), and especially between primarySUV max and peakSUV max (q = 0.88, P = 0.001). However, in a multivariate survival analysis, a significant association with OS was found only for meanSUV max . When primarySUV max and peakSUV max were used as the SUV variable for the analysis of OS, adjusted hazard ratios for death were 1.26 (95% CI, 0.60-2.06; P = 0.53) and 1.17 (95% CI, 0.56-2.46; P = 0.66), respectively. Similar results were obtained for the analysis of PFS.
Discussion
To our knowledge, this is the first study to evaluate clinical usefulness of 18 F-FDG uptake in predicting survival in SCLC patients, using carefully staged subjects who underwent homogenous treatments. In a multivariate analysis, mean-SUV max was revealed as another significant predictor of survival of SCLC together with well-defined existing prognostic factors, such as performance status, LDH, and tumor stage. Moreover, stratifying subjects by the combined criteria of meanSUV max and two-tiered staging system, we found that patients with ED and high meanSUV max , those with one of these risk factors and those without both of these risk factors had significantly different prognoses.
In the classification of SCLC, the heterogeneity of a two-stage Veterans Administration Lung Study Group system has continued to be a matter of debate. Recently, the International Association for the Study of Lung Cancer has attempted to overcome these limitations of the Veterans Administration Lung Study Group system through application of the tumornode-metastasis system (22) . Similar to the International Association for the Study of Lung Cancer study, the present study confirmed that metabolic stage can be used to identify subgroups with distinct prognosis within the broad definitions of LD-or ED-SCLC. This result is supported by the fact that 18 F-FDG-PET imaging can provide more accurate prognostic information because the metabolic process precedes gross anatomic changes. As a consequence, the combined criteria of an anatomic assessment of total tumor load in the body and a metabolic assessment of tumor aggressiveness seemed to be adequate to achieve high discriminative power for prediction of survival in SCLC. Simple prognostic factors, such as LDH, can also be included in a model to predict survival in combination with tumor stage. However, 18 F-FDG uptake has an advantage of site specificity because it is accompanied with anatomic information. In addition, it is applicable to the full spectrum of the SCLC populations, in contrast to LDH, which is rarely elevated in LD (23, 24) .
An incorporation of meanSUV max to a two-tiered staging system identified a subgroup of patients at a higher risk for death within the same stage. New treatment strategies are required for these higher risk groups identified by mean-SUV max . For example, LD patients with high meanSUV max need to take more enhanced systemic chemotherapy than the low meanSUV max group because they relapsed more frequently as distant metastasis. Combinations of chemoradiotherapy and induction chemotherapy or chemoradiotherapy and consolidation chemotherapy using non -cross-resistant drugs may help these higher risk subsets in the LD-SCLC (25 -27) . Furthermore, risk-adapted therapies also have to apply to patients with ED. Especially, more effective complements to standard systemic chemotherapy, such as maintenance therapy using new chemotherapeutic drugs or target agents, may be useful for ED patients with high meanSUV max (28 -31) .
In terms of response, the relationship between tumor response and FDG uptake remain controversial. Lee et al. (32) suggested that high SUV tumors exhibit higher response to chemotherapy but shorter time to progression. However, another report by Na et al. (33) came to a rather different conclusion that high SUV predict both unfavorable response and survival. In the present study, there was no correlation between meanSUV max and response rate. Several factors may explain this discrepancy. First, it may come from an inaccuracy of response evaluation tools. The specificity for the differentiation of residual cancer from scar tissue or fibrosis is decreased in the conventional imaging techniques. Second, the relationships among pretreatment SUV, response rate, and survival may be quite different depending on the biological intrinsic characteristics of tumor cells, treatment modality, and chemotherapeutic agents. Therefore, it is difficult to reach definitive conclusions from the previous results until now. More inclusive studies are warranted to deduce consistent conclusions.
Although SUV is widely used as a semiquantitative index to assess the tissue glucose metabolic rate, there is no standard method for the measurement or calculation of FDG. In the present study, SUV max was chosen as a calculation tool for tumor uptake because of its reproducibility. In addition, we hypothesized that the average of all the SUV max values identified would represent a surrogate marker for real tumor metabolic activity in SCLC. Consequently, of the three SUV variables tested, the meanSUV max showed the strongest association with survival in SCLC. This suggests that mean-SUV max represents the metabolic activity of the total ongoing process in the entire body. This result may be due to the biological characteristics of SCLC; that is, an early, active, and extensive dissemination. However, this calculation method for FDG needs to be validated in further prospective studies.
Our study had several limitations. First, although the median size of total lesions was larger than 2.0 cm and was not different between LD and ED subgroups, some lesions with diameter less than 2.0 cm may encounter partial volume effect. Second, because all FDG-PET abnormal lesions were measured, the number of false positives included in the analysis may be increased although possible imaging methods and pathologic biopsy were done in the case with discrepancy in PET image and CT findings.
In conclusion, the assessment of metabolic activity by pretreatment 18 F-FDG-PET/CT well predicted prognosis of SCLC patients. Incorporation of metabolic measurements by FDG-PET into a two-tiered staging system is more accurate for predicting survival than the tumor stage alone and identifies three subgroups with different prognosis. This criterion with high discriminative power will be useful for stratifying patients in randomized clinical studies and ultimately for selecting appropriate therapies.
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